Regulation and dysregulation of Epstein-Barr virus latency: Implications for the development of autoimmune diseases

被引:145
|
作者
Niller, Hans Helmut [2 ]
Wolf, Hans [2 ]
Minarovits, Janos [1 ]
机构
[1] Natl Ctr Epidemiol, Microbiol Res Grp, H-1529 Budapest, Hungary
[2] Univ Regensburg, Dept Microbiol & Hyg, D-93053 Regensburg, Germany
关键词
Epstein-Barr virus; latency control; epigenetic regulation; autoimmune diseases; B-cell tolerance checkpoints; immune surveillance defects;
D O I
10.1080/08916930802024772
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Epstein-Barr virus (EBV) is a human herpesvirus hiding in a latent form in memory B cells in the majority of the world population. Although, primary EBV infection is asymptomatic or causes a self-limiting disease, infectious mononucleosis, the virus is associated with a wide variety of neoplasms developing in immunosuppressed or immunodeficient individuals, but also in patients with an apparently intact immune system. In memory B cells, tumor cells, and lymphoblastoid cell lines (LCLs, transformed by EBV in vitro) the expression of the viral genes is highly restricted. There is no virus production (lytic viral replication associated with the expression of all viral genes) in tight latency. The expression of latent viral oncogenes and RNAs is under a strict epigenetic control via DNA methylation and histone modifications that results either in a complete silencing of the EBV genome in memory B cells, or in a cell-type dependent usage of latent promoters in tumor cells, germinal center B cells, and LCLs. Both the latent and lytic EBV proteins are potent immunogens and elicit vigorous B- and T-cell responses. In immunosuppressed and immunodeficient patients, or in individuals with a functional defect of EBV-specific T cells, lytic EBV replication is regularly activated and an increased viral load can be detected in the blood. Enhanced lytic replication results in new infection events and EBV-associated transformation events, and seems to be a risk factor both for malignant transformation and the development of autoimmune diseases. One may speculate that an increased load or altered presentation of a limited set of lytic or latent EBV proteins that cross-react with cellular antigens triggers and perpetuates the pathogenic processes that result in multiple sclerosis, systemic lupus erythematosus (SLE), and rheumatoid arthritis. In addition, in SLE patients EBV may cause defects of B-cell tolerance checkpoints because latent membrane protein 1, an EBV-encoded viral oncoprotein can induce BAFF, a B-cell activating factor that rescues self-reactive B cells and induces a lupus-like autoimmune disease in transgenic mice.
引用
收藏
页码:298 / 328
页数:31
相关论文
共 50 条
  • [41] Thalidomide, Lenalidomide and Pomalidomide Disrupt Epstein-Barr Virus (EBV) Latency: Clinical Implications
    Jones, Richard Julian
    Kenney, Shannon C.
    Dawson, Christopher
    Orlowski, Robert Z.
    BLOOD, 2013, 122 (21)
  • [42] Epstein-Barr virus serology in patients with autoimmune thyroiditis
    Vrbikova, J
    Janatkova, I
    Zamrazil, V
    Tomiska, F
    Fucikova, T
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 1996, 104 (01) : 89 - 92
  • [43] Autoimmune thrombocytopenia associated with Epstein-Barr virus infection
    González, FJC
    David, MM
    Díez, EF
    Monserrate, IC
    González-Elipe, PV
    REVISTA CLINICA ESPANOLA, 2000, 200 (05): : 292 - 293
  • [44] EPSTEIN-BARR VIRUS BEHAVIOR IN DIFFERENT POPULATIONS AND IMPLICATIONS FOR CONTROL OF EPSTEIN-BARR VIRUS-ASSOCIATED TUMORS
    DETHE, G
    CANCER RESEARCH, 1976, 36 (02) : 692 - 695
  • [45] The role of microRNAs in Epstein-Barr virus latency and lytic reactivation
    Forte, Eleonora
    Luftig, Micah A.
    MICROBES AND INFECTION, 2011, 13 (14-15) : 1156 - 1167
  • [46] Host genetics of Epstein-Barr virus infection, latency and disease
    Houldcroft, Charlotte J.
    Kellam, Paul
    REVIEWS IN MEDICAL VIROLOGY, 2015, 25 (02) : 71 - 84
  • [47] Methionine restriction forces Epstein-Barr virus out of latency
    Kashyap, Sriraksha Bharadwaj
    Mulondo, Racheal
    Mullen, Peter J.
    CELL METABOLISM, 2022, 34 (09) : 1229 - +
  • [48] Chromatin profiling of Epstein-Barr virus latency control region
    Day, Latasha
    Chau, Charles M.
    Nebozhyn, Michael
    Rennekamp, Andrew J.
    Showe, Michael
    Lieberman, Paul M.
    JOURNAL OF VIROLOGY, 2007, 81 (12) : 6389 - 6401
  • [49] Identification of Host Biomarkers of Epstein-Barr Virus Latency IIb and Latency III
    Messinger, Joshua E.
    Dai, Joanne
    Stanland, Lyla J.
    Price, Alexander M.
    Luftig, Micah A.
    MBIO, 2019, 10 (04):
  • [50] MYC MAINTAINS EPSTEIN-BARR VIRUS LATENCY IN BURKITT LYMPHOMA
    不详
    CANCER DISCOVERY, 2020, 10 (06) : 761 - 761